Guanylyl Cyclase C Messenger RNA is a Biomarker for Recurrent Stage II Colorectal Cancer

Burt Cagir, Alyssa Gelmann, Jason Park, et al.
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001

Share article


Imprima English

Reviewers: Li Liu, MD
Source: Annals of Internal Medicine, 131(11): 805-812, December 1999.


Précis: In this study, expression of guanylyl cyclase C mRNA appeared to be strongly associated with the presence of colorectal cancer micrometastases that could not be detected by standard histopathologic examination.

Introduction

The decision to administer adjuvant chemotherapy to patients with colorectal cancer is primarily based on tumor staging. Lymph node involvement is a critical component of the staging system. Various methods have been utilized in addition to conventional microscopic exam to increase the sensitivity and specificity of identifying tumor cells in the lymph nodes. Dr. Cagir and his colleagues form Thomas Jefferson University Medical Center examined the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer.

Method

mRNA in lymph nodes from 21 patients with node-negative colorectal cancer who had undergone surgery were analyzed using reverse transcriptase polymerase chain reaction (RT-PCR). Of these, 11 patients had no evidence of disease for 6 or more years after surgery, and 10 developed metastases within 3 years after surgery.

Results

  • Expression of guanylyl cyclase C mRNA was found in all patients with recurrent disease but not in those without recurrent disease.

  • Carcinoembryonic antigen (CEA) mRNA was found in only one of the 10 patients with recurrent disease.

Discussion

Expression of guanylyl cyclase C mRNA appeared to be strongly associated with the presence of colorectal cancer micrometastases that could not be detected by standard histopathologic examination. This study may help physicians to identify the subgroup of patients with colorectal cancer who may benefit from early administration of adjuvant chemotherapy.

Imprima English
News
ColoPrint predicts recurrence risk in patients with localized, stage II disease

Jan 20, 2011 - A novel microarray-based genetic test, ColoPrint, appears to effectively determine the risk of colorectal cancer recurrence among patients with localized, stage II disease, according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 20 to 22 in San Francisco.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información